BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34336894)

  • 1. Mucosal Healing Effectiveness and Safety of Anaprazole, a Novel PPI, vs. Rabeprazole in Patients With Duodenal Ulcers: A Randomized Double-Blinded Multicenter Phase II Clinical Trial.
    Shu X; Zhu Z; Fu Y; Zhang Z; Wang J; Li X; He S; Fan H; Liu S; Zhang G; Tang J; Huang C; Du Q; Wang X; Xu B; Du Y; Chen Q; Wang B; Chen Y; Duan X; Xie Y; Huo L; Hou X; Lu N
    Front Med (Lausanne); 2021; 8():690995. PubMed ID: 34336894
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect and safety of anaprazole in the treatment of duodenal ulcers: a randomized, rabeprazole-controlled, phase III non-inferiority study.
    Zhu H; Pan X; Zhang L; Sun H; Fan H; Pan Z; Huang C; Shi Z; Ding J; Wang Q; Du Y; Lyu N; Li Z
    Chin Med J (Engl); 2022 Dec; 135(24):2941-2949. PubMed ID: 36580650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
    Langtry HD; Markham A
    Drugs; 1999 Oct; 58(4):725-42. PubMed ID: 10551440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ilaprazole on the healing of endoscopic submucosal dissection-induced gastric ulcer: randomized-controlled, multicenter study.
    Bang CS; Shin WG; Seo SI; Choi MH; Jang HJ; Park SW; Kae SH; Yang YJ; Shin SP; Baik GH; Kim HY
    Surg Endosc; 2019 May; 33(5):1376-1385. PubMed ID: 30167954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of efficacy, safety and tolerability rabeprazole in treatment of acid-peptic diseases ].
    de Freitas JA; Lima LM; Ranieri JL; Olivieri JC; Fragoso HJ; Chinzon D
    Arq Gastroenterol; 2002; 39(1):60-5. PubMed ID: 12184168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of rabeprazole once daily for acid-related disorders.
    Lanza F; Bardhan KD; Perdomo C; Niecestro R; Barth J
    Dig Dis Sci; 2001 Mar; 46(3):587-96. PubMed ID: 11318537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ilaprazole Compared With Rabeprazole in the Treatment of Duodenal Ulcer: A Randomized, Double-blind, Active-controlled, Multicenter Study.
    Fan L; Xianghong Q; Ling W; Ying H; Jielai X; Haitang H
    J Clin Gastroenterol; 2019 Oct; 53(9):641-647. PubMed ID: 30789856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rabeprazole is superior to ranitidine in the management of active duodenal ulcer disease: results of a double-blind, randomized North American study.
    Breiter JR; Riff D; Humphries TJ
    Am J Gastroenterol; 2000 Apr; 95(4):936-42. PubMed ID: 10763941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study.
    Dekkers CP; Beker JA; Thjodleifsson B; Gabryelewicz A; Bell NE; Humphries TJ
    Aliment Pharmacol Ther; 1999 Feb; 13(2):179-86. PubMed ID: 10102948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials.
    Salas M; Ward A; Caro J
    BMC Gastroenterol; 2002 Jul; 2():17. PubMed ID: 12119060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
    Caro JJ; Salas M; Ward A
    Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases.
    Ji S; Kim HS; Kim JW; Jee MK; Park KW; Uh Y; Lee DK; Song JS; Baik SK; Kwon SO
    J Gastroenterol Hepatol; 2006 Sep; 21(9):1381-7. PubMed ID: 16911680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of Anaprazole versus Ilaprazole for the treatment of duodenal ulcers in China.
    Ni H; Shi J; Hu M; Zhou N; Yang S
    Front Pharmacol; 2024; 15():1407435. PubMed ID: 38910891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group.
    Cloud ML; Enas N; Humphries TJ; Bassion S
    Dig Dis Sci; 1998 May; 43(5):993-1000. PubMed ID: 9590413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated models of population pharmacokinetics and exposure response to optimize dosage regimen for anaprazole sodium in duodenal ulcer.
    Zhang L; Song L; Cui C; Wang C; Zhang Y; Yao X; Liu D
    Eur J Pharm Sci; 2024 Jul; 198():106781. PubMed ID: 38703917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy and safety of rabeprazole in patients taking low-dose aspirin with a history of peptic ulcers: a phase 2/3, randomized, parallel-group, multicenter, extension clinical trial.
    Fujishiro M; Higuchi K; Kato M; Kinoshita Y; Iwakiri R; Watanabe T; Takeuchi T; Sugisaki N; Okada Y; Ogawa H; Arakawa T; Fujimoto K;
    J Clin Biochem Nutr; 2015 May; 56(3):228-39. PubMed ID: 26060354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Similar Efficacy of Proton-Pump Inhibitors vs H2-Receptor Antagonists in Reducing Risk of Upper Gastrointestinal Bleeding or Ulcers in High-Risk Users of Low-Dose Aspirin.
    Chan FK; Kyaw M; Tanigawa T; Higuchi K; Fujimoto K; Cheong PK; Lee V; Kinoshita Y; Naito Y; Watanabe T; Ching JY; Lam K; Lo A; Chan H; Lui R; Tang RS; Sakata Y; Tse YK; Takeuchi T; Handa O; Nebiki H; Wu JC; Abe T; Mishiro T; Ng SC; Arakawa T
    Gastroenterology; 2017 Jan; 152(1):105-110.e1. PubMed ID: 27641510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised clinical trial: prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin.
    Iwakiri R; Higuchi K; Kato M; Fujishiro M; Kinoshita Y; Watanabe T; Takeuchi T; Yamauchi M; Sanomura M; Nakagawa H; Sugisaki N; Okada Y; Ogawa H; Arakawa T; Fujimoto K
    Aliment Pharmacol Ther; 2014 Oct; 40(7):780-95. PubMed ID: 25100080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The benefit/risk profile of rabeprazole, a new proton-pump inhibitor.
    Johnson D; Perdomo C; Barth J; Jokubaitis L
    Eur J Gastroenterol Hepatol; 2000 Jul; 12(7):799-806. PubMed ID: 10929909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders.
    Richardson P; Hawkey CJ; Stack WA
    Drugs; 1998 Sep; 56(3):307-35. PubMed ID: 9777309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.